Merck chopping 140-plus staffers out of Acceleron in wake of $11.5B buyout
Four months after Merck closed its $11.5 billion acquisition of Acceleron, the pharma giant helped cover the tab by chopping out more than 140 staffers from the newly acquired biotech. But they’re not all getting pink slipped. Around 120 Acceleron employees now have new posts inside Merck, the pharma giant tells us.
Merck posted a WARN notice on the layoffs this week, alerting the state of Massachusetts of plans to cut 170 staffers in Cambridge, MA. At the end of 2020, Acceleron had 312 full timers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
